The U.S. District Court for the District of Hawaii Feb. 23 denied a preliminary injunction requested by AstraZeneca in a case challenging the state’s law protecting 340B pricing for contract pharmacy arrangements. The court held that Hawaii’s law is not preempted by the federal law, does not violate the Constitution’s spending clause and does not discriminate against federal contractors. “At least at this stage, AstraZeneca has not shown a likelihood of success on — or even serious questions going to — the merits of this argument,” the court wrote in its ruling. 

Headline
A bipartisan group of senators Aug. 5 introduced the Supporting Underserved and Strengthening Transparency, Accountability and Integrity Now and for the Future…
Headline
The Department of Health and Human Services today issued a notice announcing a revised 340B Rebate Model Pilot Program, allowing qualifying drug manufacturers…
Headline
The U.S. District Court for the District of Columbia July 21 upheld a lower court’s decision that Section 340B of the Public Health Service Act does not …
Headline
The AHA July 14 urged the Health Resources and Services Administration to revise its estimate of the administrative burden associated with the agency’s…
Headline
The AHA today filed a friend-of-the-court brief supporting the Department of Health and Human Services’ motion to dismiss AbbVie’s lawsuit …
Headline
The Health Resources and Services Administration announced that 340B covered entities purchased $100 billion in outpatient drugs under the federal 340B Drug…